Drug intelligence / Profile preview

FORT-202

Development stage: Preclinical
Lead developer: Fortitude Biomedicines
Modality: Antibody-Based Therapeutics

Overview

FORT-202 is the lead therapeutic candidate developed by Fortitude Biomedicines, an antibody-focused biotechnology company. It is an immune cell-targeting biologic designed for the treatment of autoimmune diseases and cancer. As of early 2024, the program is advancing through IND-enabling studies. While specific target details remain undisclosed, the development of FORT-202 is supported by the company's broader expertise in antibody-based therapies and its proprietary GLUE-DAC platform. This platform, originally developed at Baylor College of Medicine, represents a next-generation antibody-drug conjugate (ADC) technology that utilizes molecular glue payloads for targeted protein degradation (TPD).

Beyond the preview

Go deeper on FORT-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FORT-202.

Explore the full profile